Whitehawk Therapeutics Inc (WHWK) — Financial statements
Income statement, balance sheet, and cash flow for Whitehawk Therapeutics Inc — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 7↓72.5% | 26↑6.7% | 24↑60.1% | 15↑1258.6% | 1 | |
| Cost of Revenue | 0.76↓98.6% | 54↑4.5% | 52↑52.2% | 34↑72.8% | 20 | |
| Gross Profit | 6↑122.7% | -28↓2.5% | -27↓45.8% | -19↓1.2% | -19 | |
| Operating Expenses | ||||||
| R&D Expenses | 91↑78.3% | 51↑4.3% | 49↑49.8% | 33↑66.0% | 20 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 19 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 30↓18.8% | 37↓17.5% | 45↑10.9% | 40↑117.0% | 19 | |
| Other Expenses | 0.00↑100.0% | -48↑1.1% | -49↓69.1% | -29↓153.1% | 54 | |
| Operating Expenses | 121↑206.7% | 39↓11.6% | 45↑1.5% | 44↓52.6% | 93 | |
| Total Costs & Expenses | 122↑30.1% | 93↓3.0% | 96↑23.6% | 78↓30.7% | 112 | |
| Operating Results | ||||||
| Operating Income | -114↓69.6% | -67↑6.2% | -72↓14.8% | -63↑43.6% | -111 | |
| Depreciation & Amortization | 0.00↓100.0% | 0.19↑14.2% | 0.17↑6.3% | 0.16↑51.4% | 0.11 | |
| EBITDA | -114↓77.0% | -65↑9.9% | -72↓22.1% | -59↓59.1% | -37 | |
| EBIT | -114↓76.5% | -65↑9.9% | -72↓22.0% | -59↓59.1% | -37 | |
| Interest & Other Income | ||||||
| Net Interest Income | 6↑65.2% | 4↓38.9% | 6↑184.5% | 2↑432.5% | -0.65 | |
| Interest Income | 6↑58.8% | 4↓38.7% | 6↑166.9% | 2↑18346.2% | 0.01 | |
| Interest Expense | 0.00↓100.0% | 0.15↓33.3% | 0.23↑0.4% | 0.23↓65.4% | 0.67 | |
| Non-Operating Income | 0.00↑100.0% | -3 | 0.00↑100.0% | -4↑95.0% | -74 | |
| Other Income / Expenses | 94↑2390.2% | 4↓38.9% | 6↑184.5% | 2↑92.0% | 1 | |
| Income Before Tax | -21↑67.7% | -64↑3.2% | -66↓8.7% | -61↑45.0% | -110 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -21↑67.7% | -64↑3.2% | -66↓8.7% | -61↑45.0% | -110 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -21↑67.7% | -64↑3.2% | -66↓8.7% | -61↑45.0% | -110 | |
| Bottom-Line Net Income | -21↑67.7% | -64↑3.2% | -66↓8.7% | -61↑45.4% | -111 | |
| EPS (Basic) | -0.33↑86.0% | -2.36↑3.3% | -2.44↑9.3% | -2.69↑78.3% | -12.41 | |
| EPS (Diluted) | -0.33↑86.0% | -2.36↑3.3% | -2.44↑9.3% | -2.69↑78.3% | -12.41 | |
| Weighted Average Shares | 62↑129.0% | 27↑0.4% | 27↑19.6% | 23↑153.8% | 9 | |
| Weighted Average Diluted Shares | 62↑129.0% | 27↑0.4% | 27↑19.6% | 23↑152.3% | 9 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.